Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.255
+0.025 (2.06%)
At close: Mar 13, 2026, 4:00 PM EDT
1.250
-0.005 (-0.42%)
After-hours: Mar 13, 2026, 7:25 PM EDT

Revelation Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
5.014.434.515.495.04
Research & Development
4.063.554.155.386.91
Total Operating Expenses
9.077.988.6610.8611.95
Operating Income
-9.07-7.98-8.66-10.86-11.95
Other Non-Operating Income (Expense)
0.16-7.068.540.03-0.04
Total Non-Operating Income (Expense)
0.16-7.068.540.03-0.04
Pretax Income
-8.91-15.04-0.12-10.83-11.99
Net Income
-23.78-30.08-0.12-10.83-11.99
Net Income to Common
-23.78-30.08-0.12-10.83-11.99
Shares Outstanding (Basic)
10000
Shares Outstanding (Diluted)
10000
Shares Change (YoY)
4243.28%1103.96%214.03%672.09%309.60%
EPS (Basic)
-23.95-1052.16-101.28-28646.40-244800.00
EPS (Diluted)
-23.95-1052.16-101.28-28646.40-244800.00
Free Cash Flow
-8.27-18.34-7.29-11.22-11.22
Free Cash Flow Per Share
-13.32-1283.18-6137.54-29677.26-229197.82
EBITDA
-9.04-7.95-8.63-10.84-11.93
EBIT
-9.07-7.98-8.66-10.86-11.95
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q